Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 81 articles:
HTML format



Single Articles


    November 2022
  1. LI C, Lee H, Jung JH, Zhang Y, et al
    Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from proteasome-mediated degradation.
    Oncogene. 2022 Nov 17. pii: 10.1038/s41388-022-02541.
    PubMed     Abstract available


  2. LI M, Tsavachidis S, Wang F, Bui T, et al
    Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer.
    Oncogene. 2022 Nov 7. pii: 10.1038/s41388-022-02527.
    PubMed     Abstract available


  3. KLOUCH KZ, Stern MH, Trabelsi-Grati O, Kiavue N, et al
    Microsatellite instability detection in breast cancer using drop-off droplet digital PCR.
    Oncogene. 2022 Nov 3. pii: 10.1038/s41388-022-02504.
    PubMed     Abstract available


  4. HU H, Zhang H, Xing Y, Zhou Y, et al
    The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer.
    Oncogene. 2022 Nov 3. pii: 10.1038/s41388-022-02495.
    PubMed     Abstract available


  5. BLAZQUEZ R, Chuang HN, Wenske B, Trigueros L, et al
    Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain.
    Oncogene. 2022;41:5008-5019.
    PubMed     Abstract available


    October 2022
  6. UNLU B, Kocaturk B, Rondon AMR, Lewis CS, et al
    Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer.
    Oncogene. 2022 Oct 21. pii: 10.1038/s41388-022-02511.
    PubMed     Abstract available


  7. TWAFRA S, Sokolik CG, Sneh T, Srikanth KD, et al
    A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis.
    Oncogene. 2022 Oct 18. pii: 10.1038/s41388-022-02481.
    PubMed     Abstract available


  8. YOUSEFI H, Khosla M, Lauterboeck L, Okpechi SC, et al
    A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming.
    Oncogene. 2022 Oct 15. pii: 10.1038/s41388-022-02497.
    PubMed     Abstract available


  9. DUNN S, Eberlein C, Yu J, Gris-Oliver A, et al
    AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
    Oncogene. 2022 Oct 14. pii: 10.1038/s41388-022-02482.
    PubMed     Abstract available


  10. HARROD A, Lai CF, Goldsbrough I, Simmons GM, et al
    Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
    Oncogene. 2022 Oct 5. pii: 10.1038/s41388-022-02483.
    PubMed     Abstract available


    September 2022
  11. LI Y, Deng Y, Zhao Y, Zhang W, et al
    Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02459.
    PubMed     Abstract available


    August 2022
  12. VULIN M, Jehanno C, Sethi A, Correia AL, et al
    A high-throughput drug screen reveals means to differentiate triple-negative breast cancer.
    Oncogene. 2022 Aug 25. pii: 10.1038/s41388-022-02429.
    PubMed     Abstract available


  13. WEI L, Wang W, Yao J, Cui Z, et al
    PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation.
    Oncogene. 2022 Aug 16. pii: 10.1038/s41388-022-02431.
    PubMed     Abstract available


  14. MORALES-VALENCIA J, Lau L, Marti-Nin T, Ozerdem U, et al
    Therapy-induced senescence promotes breast cancer cells plasticity by inducing Lipocalin-2 expression.
    Oncogene. 2022 Aug 11. pii: 10.1038/s41388-022-02433.
    PubMed     Abstract available


  15. OH KS, Nam AR, Bang JH, Seo HR, et al
    A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers.
    Oncogene. 2022;41:3939-3952.
    PubMed     Abstract available


  16. TARANTINO D, Walker C, Weekes D, Pemberton H, et al
    Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance.
    Oncogene. 2022;41:3969-3977.
    PubMed     Abstract available


  17. BELLENGHI M, Talarico G, Botti L, Puglisi R, et al
    SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model.
    Oncogene. 2022;41:4055-4065.
    PubMed     Abstract available


    July 2022
  18. BELL ES, Shah P, Zuela-Sopilniak N, Kim D, et al
    Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer.
    Oncogene. 2022 Jul 27. pii: 10.1038/s41388-022-02420.
    PubMed     Abstract available


  19. GU Y, Gao H, Zhang H, John A, et al
    TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer.
    Oncogene. 2022 Jul 21. pii: 10.1038/s41388-022-02415.
    PubMed     Abstract available


  20. LIU C, Wang J, Zheng Y, Zhu Y, et al
    Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin alphavbeta3.
    Oncogene. 2022 Jul 19. pii: 10.1038/s41388-022-02409.
    PubMed     Abstract available


  21. QUEK LE, van Geldermalsen M, Guan YF, Wahi K, et al
    Glutamine addiction promotes glucose oxidation in triple-negative breast cancer.
    Oncogene. 2022 Jul 18. pii: 10.1038/s41388-022-02408.
    PubMed     Abstract available


    June 2022
  22. SHEN J, Huang Q, Jia W, Feng S, et al
    YAP1 induces invadopodia formation by transcriptionally activating TIAM1 through enhancer in breast cancer.
    Oncogene. 2022 Jun 30. pii: 10.1038/s41388-022-02344.
    PubMed     Abstract available


  23. BUSCHHAUS JM, Rajendran S, Humphries BA, Cutter AC, et al
    Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer.
    Oncogene. 2022 Jun 22. pii: 10.1038/s41388-022-02385.
    PubMed     Abstract available


  24. RONG Z, Zhang L, Li Z, Xiao Z, et al
    Correction: SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling.
    Oncogene. 2022 Jun 14. pii: 10.1038/s41388-022-02374.
    PubMed    


  25. KUMARASAMY V, Nambiar R, Wang J, Rosenheck H, et al
    RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.
    Oncogene. 2022 Jun 9. pii: 10.1038/s41388-022-02362.
    PubMed     Abstract available


  26. MEIJER TG, Nguyen L, Van Hoeck A, Sieuwerts AM, et al
    Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Oncogene. 2022;41:3498-3506.
    PubMed     Abstract available


    May 2022
  27. RATZE MAK, Koorman T, Sijnesael T, Bassey-Archibong B, et al
    Correction: Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
    Oncogene. 2022 May 24. pii: 10.1038/s41388-022-02355.
    PubMed    


  28. ZHAO Y, Sun H, Zhao Y, Liu Q, et al
    NSrp70 suppresses metastasis in triple-negative breast cancer by modulating Numb/TbetaR1/EMT axis.
    Oncogene. 2022 May 14. pii: 10.1038/s41388-022-02349.
    PubMed     Abstract available


  29. SIMOND AM, Bui T, Zuo D, Sanguin-Gendreau V, et al
    Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer.
    Oncogene. 2022 May 10. pii: 10.1038/s41388-022-02323.
    PubMed     Abstract available


  30. KIM JY, Cho TM, Park JM, Park S, et al
    A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.
    Oncogene. 2022 May 2. pii: 10.1038/s41388-022-02269.
    PubMed     Abstract available


  31. LIM JS, Lee KW, Ko KP, Jeong SI, et al
    XAF1 destabilizes estrogen receptor alpha through the assembly of a BRCA1-mediated destruction complex and promotes estrogen-induced apoptosis.
    Oncogene. 2022;41:2897-2908.
    PubMed     Abstract available


  32. CHADET S, Allard J, Brisson L, Lopez-Charcas O, et al
    P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition.
    Oncogene. 2022;41:2920-2931.
    PubMed     Abstract available


  33. PANG Z, Dong X, Deng H, Wang C, et al
    MUC1 triggers lineage plasticity of Her2 positive mammary tumors.
    Oncogene. 2022;41:3064-3078.
    PubMed     Abstract available


    April 2022
  34. KIM Y, Ko JY, Lee SB, Oh S, et al
    Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer.
    Oncogene. 2022 Apr 30. pii: 10.1038/s41388-022-02326.
    PubMed     Abstract available


  35. RATZE MAK, Koorman T, Sijnesael T, Bassey-Archibong B, et al
    Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
    Oncogene. 2022 Apr 18. pii: 10.1038/s41388-022-02314.
    PubMed     Abstract available


  36. WU S, Guo B, Zhang L, Zhu X, et al
    A micropeptide XBP1SBM encoded by lncRNA promotes angiogenesis and metastasis of TNBC via XBP1s pathway.
    Oncogene. 2022;41:2163-2172.
    PubMed     Abstract available


    March 2022
  37. BERTOLINI I, Perego M, Ghosh JC, Kossenkov AV, et al
    NFkappaB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment.
    Oncogene. 2022 Mar 30. pii: 10.1038/s41388-022-02280.
    PubMed     Abstract available


  38. YANG YS, Jia XZ, Lu QY, Cai SL, et al
    Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells.
    Oncogene. 2022 Mar 29. pii: 10.1038/s41388-022-02278.
    PubMed     Abstract available


  39. KOORMAN T, Jansen KA, Khalil A, Haughton PD, et al
    Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment.
    Oncogene. 2022 Mar 15. pii: 10.1038/s41388-022-02258.
    PubMed     Abstract available


  40. RONG Z, Zhang L, Li Z, Xiao Z, et al
    SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling.
    Oncogene. 2022 Mar 11. pii: 10.1038/s41388-022-02259.
    PubMed     Abstract available


  41. LIU R, Yang G, Bao M, Zhou Z, et al
    STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression.
    Oncogene. 2022 Mar 2. pii: 10.1038/s41388-022-02252.
    PubMed     Abstract available


    February 2022
  42. TURDO A, Gaggianesi M, Di Franco S, Veschi V, et al
    Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51.
    Oncogene. 2022 Feb 25. pii: 10.1038/s41388-022-02239.
    PubMed     Abstract available


  43. LIU Y, Ma L, Hua F, Min Z, et al
    Correction: Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer.
    Oncogene. 2022 Feb 22. pii: 10.1038/s41388-022-02217.
    PubMed    


  44. ZHANG Y, Dho SE, Othman K, Simpson CD, et al
    Numb exon 9 inclusion regulates Integrinbeta5 surface expression and promotes breast cancer metastasis.
    Oncogene. 2022 Feb 18. pii: 10.1038/s41388-022-02225.
    PubMed     Abstract available


  45. SUN T, Wu Z, Wang X, Wang Y, et al
    Correction to: LNC942 promoting METTL14-mediated m 6 A methylation in breast cancer cell proliferation and progression.
    Oncogene. 2022 Feb 15. pii: 10.1038/s41388-022-02194.
    PubMed    


  46. GUO XY, Liu TT, Zhu WJ, Liu HT, et al
    CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis.
    Oncogene. 2022 Feb 11. pii: 10.1038/s41388-022-02232.
    PubMed     Abstract available


  47. XU LM, Zhang J, Ma Y, Yuan YJ, et al
    MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG.
    Oncogene. 2022 Feb 4. pii: 10.1038/s41388-022-02211.
    PubMed     Abstract available


  48. MA A, Tang M, Zhang L, Wang B, et al
    Correction to: USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis.
    Oncogene. 2022 Feb 3. pii: 10.1038/s41388-022-02215.
    PubMed    


  49. BIONDINI M, Kiepas A, El-Houjeiri L, Annis MG, et al
    HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
    Oncogene. 2022 Feb 2. pii: 10.1038/s41388-022-02206.
    PubMed     Abstract available


    January 2022
  50. HOWLEY BV, Mohanty B, Dalton A, Grelet S, et al
    The ubiquitin E3 ligase ARIH1 regulates hnRNP E1 protein stability, EMT and breast cancer progression.
    Oncogene. 2022 Jan 31. pii: 10.1038/s41388-022-02199.
    PubMed     Abstract available


  51. ZOU H, Luo J, Guo Y, Liu Y, et al
    RNA-binding protein complex LIN28/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7.
    Oncogene. 2022 Jan 31. pii: 10.1038/s41388-022-02198.
    PubMed     Abstract available


  52. MA Y, Zhang H, Chen C, Liu L, et al
    TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer.
    Oncogene. 2022 Jan 28. pii: 10.1038/s41388-022-02204.
    PubMed     Abstract available


  53. ZIGROSSI A, Hong LK, Ekyalongo RC, Cruz-Alvarez C, et al
    SELENOF is a new tumor suppressor in breast cancer.
    Oncogene. 2022 Jan 27. pii: 10.1038/s41388-021-02158.
    PubMed     Abstract available


  54. OKPECHI SC, Yousefi H, Nguyen K, Cheng T, et al
    Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.
    Oncogene. 2022 Jan 22. pii: 10.1038/s41388-021-02150.
    PubMed     Abstract available


  55. AVALLE L, Raggi L, Monteleone E, Savino A, et al
    STAT3 induces breast cancer growth via ANGPTL4, MMP13 and STC1 secretion by cancer associated fibroblasts.
    Oncogene. 2022 Jan 18. pii: 10.1038/s41388-021-02172.
    PubMed     Abstract available


  56. LIU Y, Ma L, Hua F, Min Z, et al
    Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer.
    Oncogene. 2022 Jan 13. pii: 10.1038/s41388-021-02061.
    PubMed     Abstract available


  57. SHU L, Chen A, Li L, Yao L, et al
    NRG1 regulates Fra-1 transcription and metastasis of triple-negative breast cancer cells via the c-Myc ubiquitination as manipulated by ERK1/2-mediated Fbxw7 phosphorylation.
    Oncogene. 2022 Jan 7. pii: 10.1038/s41388-021-02142.
    PubMed     Abstract available


  58. BUI T, Gu Y, Ancot F, Sanguin-Gendreau V, et al
    Emergence of beta1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment.
    Oncogene. 2022;41:527-537.
    PubMed     Abstract available


  59. CICEK E, Circir A, Oyken M, Akbulut Caliskan O, et al
    EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers.
    Oncogene. 2022;41:220-232.
    PubMed     Abstract available


  60. KUIKEN HJ, Dhakal S, Selfors LM, Friend CM, et al
    Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts.
    Oncogene. 2022;41:112-124.
    PubMed     Abstract available


    December 2021
  61. ZHANG S, Guo X, Liu X, Zhong Z, et al
    Correction to: Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation.
    Oncogene. 2021 Dec 20. pii: 10.1038/s41388-021-02129.
    PubMed    


  62. CAO X, Geradts J, Dewhirst MW, Lo HW, et al
    Correction: Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.
    Oncogene. 2021 Dec 9. pii: 10.1038/s41388-021-02043.
    PubMed    


    November 2021
  63. KONG Y, Zhang Y, Wang H, Kan W, et al
    Inner nuclear membrane protein TMEM201 promotes breast cancer metastasis by positive regulating TGFbeta signaling.
    Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02098.
    PubMed     Abstract available


  64. LI Y, Liu HT, Chen X, Wang YW, et al
    Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer.
    Oncogene. 2021 Nov 9. pii: 10.1038/s41388-021-02083.
    PubMed     Abstract available


  65. RUIZ-TORRES SJ, Bourn JR, Benight NM, Hunt BG, et al
    Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35.
    Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02091.
    PubMed     Abstract available


  66. YI B, Wang S, Wang X, Liu Z, et al
    CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer.
    Oncogene. 2021 Nov 2. pii: 10.1038/s41388-021-02089.
    PubMed     Abstract available


  67. ROUKENS MG, Frederiks CL, Seinstra D, Braccioli L, et al
    Regulation of a progenitor gene program by SOX4 is essential for mammary tumor proliferation.
    Oncogene. 2021;40:6343-6353.
    PubMed     Abstract available


  68. BOLADO-CARRANCIO A, Lee M, Ewing A, Muir M, et al
    ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling.
    Oncogene. 2021;40:6235-6247.
    PubMed     Abstract available


    October 2021
  69. TANG SC, Lion Q, Peulen O, Chariot P, et al
    The E3 ligase COP1 promotes ERalpha signaling and suppresses EMT in breast cancer.
    Oncogene. 2021 Oct 29. pii: 10.1038/s41388-021-02038.
    PubMed     Abstract available


  70. CHERADAME L, Guerrera IC, Gaston J, Schmitt A, et al
    STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway.
    Oncogene. 2021 Oct 8. pii: 10.1038/s41388-021-02037.
    PubMed     Abstract available


  71. BLOCK CJ, Mitchell AV, Wu L, Glassbrook J, et al
    RNA binding protein RBMS3 is a common EMT effector that modulates triple-negative breast cancer progression via stabilizing PRRX1 mRNA.
    Oncogene. 2021 Oct 4. pii: 10.1038/s41388-021-02030.
    PubMed     Abstract available


    September 2021
  72. PALMA FR, Ratti BA, Paviani V, Coelho DR, et al
    AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism.
    Oncogene. 2021;40:5455-5467.
    PubMed     Abstract available


    August 2021
  73. MAJHI PD, Griner NB, Mayfield JA, Compton S, et al
    Genetic modifiers regulating DNA replication and double-strand break repair are associated with differences in mammary tumors in mouse models of Li-Fraumeni syndrome.
    Oncogene. 2021;40:5026-5037.
    PubMed     Abstract available


    July 2021
  74. ZHANG J, Liu Y, Tan J, Zhang Y, et al
    Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC.
    Oncogene. 2021;40:4783-4795.
    PubMed     Abstract available


  75. ZHAO Z, Guo Y, Liu Y, Sun L, et al
    Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer.
    Oncogene. 2021;40:4604-4614.
    PubMed     Abstract available


  76. LIU X, Li L, Si F, Huang L, et al
    NK and NKT cells have distinct properties and functions in cancer.
    Oncogene. 2021;40:4521-4537.
    PubMed     Abstract available


    June 2021
  77. PROKAKIS E, Dyas A, Grun R, Fritzsche S, et al
    USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response.
    Oncogene. 2021;40:4004-4018.
    PubMed     Abstract available


    April 2021
  78. MAI J, Peng XD, Tang J, Du T, et al
    AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation.
    Oncogene. 2021;40:2422-2436.
    PubMed     Abstract available


    March 2021
  79. AHMED SF, Buetow L, Gabrielsen M, Lilla S, et al
    E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Oncogene. 2021;40:2149-2164.
    PubMed     Abstract available


  80. LIN CC, Yang WH, Lin YT, Tang X, et al
    DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
    Oncogene. 2021;40:2018-2034.
    PubMed     Abstract available


  81. YE Z, Wang D, Lu Y, He Y, et al
    Vacuolin-1 inhibits endosomal trafficking and metastasis via CapZbeta.
    Oncogene. 2021;40:1775-1791.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: